A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection
Tarek Hassanein, David Gardiner(Bristol-Myers Squibb (Germany)), Lynn R. Webster(Adherent Technologies (United States)), A. Griffies(Bristol-Myers Squibb (Germany)), Michael Bennett(Associates Research), Paul J. Thuluvath(University of Maryland, Baltimore), Bhaskar Rege(Bristol-Myers Squibb (Germany)), Eric Lawitz(The University of Texas at San Antonio Health Science Center), Zobair M. Younossi(Georgetown University), Nannan Zhou(Chinese Academy of Sciences), Fiona McPhee(Bristol-Myers Squibb (United States)), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Helen Zhou(Bristol-Myers Squibb (United States)), Ellen Chung(Bristol-Myers Squibb (Germany)), Tuan Nguyen, Dennis M. Grasela(Bristol-Myers Squibb (United States)), Norman Gitlin(NYU Langone Health), Howard Schwartz(Clinical Research Associates), Karen Sims(Bristol-Myers Squibb (Germany))
Cited by 53
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k